The prognostic significance of KRAS mutations as a useful biomarker in predicting susceptibility, drug response outcomes, and survival of CRC patients has not been extensively investigated, particularly its prognostic value in metastatic CRC (mCRC). This evidence concerns the gene KRAS and colorectal carcinoma.